Cowen analyst Phil Nadeau reiterated an Outperform rating and raised estimates on Vir Biotechnology (NASDAQ: VIR) after agreements with the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE